Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 7/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6849900 | 0.98 | KDM4E (0.57) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL7672296 | 0.88 | KDM4E (0.59) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL6748722 | 0.87 | MAPT (0.61) | KDM4ESMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL28857264 | 0.85 | KDM4E (0.55) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL12669771 | 0.83 | MAPT (0.50) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL14036676 | 0.82 | NPSR1 (0.60) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL13973077 | 0.82 | G6PD (0.55) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL9826699 | 0.81 | LMNA (0.48) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL6633938 | 0.81 | CA1 (0.56) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL6213988 | 0.80 | LMNA (0.53) | KDM4ESMN1; SMN2GAAMPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111699250-A | Carboxyesterase polypeptides for amide coupling | 科德克希思公司 | 2020-09-22 | — | — | CN | claimed |
| US-6271265-B1 | N-TERT-BUTYL-2-HYDROXYBENZAMIDE FOR INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | claimed |
| EP-1077699-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059582-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| CN-111699250-B | Carboxylesterase polypeptides for amide coupling | 科德克希思公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20200317649-A1 | AZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2020-10-08 | — | — | US | disclosed |
| CN-111699250-A | Carboxyesterase polypeptides for amide coupling | 科德克希思公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-6271265-B1 | N-TERT-BUTYL-2-HYDROXYBENZAMIDE FOR INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1077699-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059582-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-4900725-A | CONTRACEPTIVES | ROUSSEL UCLAF (FR) | 1990-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | EIF2AK1, EIF2A, EIF4A2 | KDM4E 872/4885SMN1; SMN2 1193/4885GAA 1244/4885 |
| US-20200317649-A1 | AZOLE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | KDM4E 3053/4885SMN1; SMN2 4215/4885GAA 2117/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | KDM4E 1507/4885SMN1; SMN2 3654/4885GAA 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.